Gynaecological monitoring during tamoxifen therapy

The Lancet

Volumn 344, Issue 8932, 1994, Pages 1244-

  Bissett, D ^a   Davis, J A ^a   George, W D ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; TAMOXIFEN;

BREAST CANCER; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FLUSHING; GYNECOLOGIC DISEASE; GYNECOLOGY; HUMAN; NOTE; PRIORITY JOURNAL; SWEAT;

EID: 0027972048     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(94)90747-1     Document Type: Article

References (5)

1. The case for clinical trials of tamoxifen for the prevention of breast cancer
2. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
3. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
4. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers
5. Comparison of cyclical tamoxifen and megestrol acetate with tamoxifen alone in advanced breast cancer